{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T19:51:16Z","timestamp":1780948276806,"version":"3.54.1"},"reference-count":87,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2018.8803","type":"journal-article","created":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T11:38:25Z","timestamp":1527161905000},"source":"Crossref","is-referenced-by-count":10,"title":["Primary extra\u2011nodal diffuse large B\u2011cell lymphoma: A prognostic analysis of 141 patients"],"prefix":"10.3892","author":[{"given":"Haorui","family":"Shen","sequence":"first","affiliation":[{"name":"Department of Hematology, Peking Union Medical College Hospital, Beijing 100730, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking Union Medical College Hospital, Beijing 100730, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daobin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking Union Medical College Hospital, Beijing 100730, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking Union Medical College Hospital, Beijing 100730, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking Union Medical College Hospital, Beijing 100730, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking Union Medical College Hospital, Beijing 100730, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking Union Medical College Hospital, Beijing 100730, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking Union Medical College Hospital, Beijing 100730, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peking Union Medical College Hospital, Beijing 100730, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2018,5,24]]},"reference":[{"key":"key20200714083010_b1-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3109\/10428199609067590","article-title":"Primary extranodal non-Hodgkin's lymphoma in adults: Clinicopathological and survival characteristics","volume":"21","author":"Economopoulos","year":"1996","journal-title":"Leuk Lymphoma"},{"issue":"Suppl 5","key":"key20200714083010_b2-ol-0-0-8803","doi-asserted-by":"crossref","first-page":"v91","DOI":"10.1093\/annonc\/mdw175","article-title":"Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Vitolo","year":"2016","journal-title":"Ann Oncol"},{"key":"key20200714083010_b3-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/1097-0142(197808)42:2<406::AID-CNCR2820420205>3.0.CO;2-H","article-title":"Primary extranodal lymphoma: Response to treatment and factors influencing prognosis","volume":"42","author":"Rudders","year":"1978","journal-title":"Cancer"},{"key":"key20200714083010_b4-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1200\/JCO.1983.1.11.682","article-title":"Extralymphatic involvement in diffuse non-Hodgkin's lymphoma","volume":"1","author":"Paryani","year":"1983","journal-title":"J Clin Oncol"},{"key":"key20200714083010_b5-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/0277-5379(91)90081-N","article-title":"Clinicopathological features and prognostic factors in extranodal non-hodgkin lymphomas","volume":"27","author":"D'amore","year":"1991","journal-title":"Danish LYFO study group. Eur J Cancer"},{"key":"key20200714083010_b6-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1179\/102453308X316149","article-title":"Extranodal lymphoma: A comparative study","volume":"13","author":"AlShemmari","year":"2008","journal-title":"Hematology"},{"key":"key20200714083010_b7-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.leukres.2010.02.010","article-title":"Clinical features and prognostic relevance of ovarian involvement in non-Hodgkin's lymphoma: A Consortium for Improving Survival of Lymphoma (CISL) report","volume":"34","author":"Yun","year":"2010","journal-title":"Leuk Res"},{"key":"key20200714083010_b8-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/1097-0142(197201)29:1<252::AID-CNCR2820290138>3.0.CO;2-#","article-title":"Occurrence and prognosis of extranodal lymphomas","volume":"29","author":"Freeman","year":"1972","journal-title":"Cancer"},{"key":"key20200714083010_b9-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1002\/1097-0142(19801101)46:9<1925::AID-CNCR2820460906>3.0.CO;2-4","article-title":"Extranodal non-Hodgkin's lymphoma","volume":"46","author":"Reddy","year":"1980","journal-title":"Cancer"},{"key":"key20200714083010_b10-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3109\/10428194.2013.811239","article-title":"Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: A systematic review and meta-analysis","volume":"55","author":"Zhang","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"key20200714083010_b11-ol-0-0-8803","article-title":"The 2008 WHO classification of lymphomas: Implications for clinical practice and translational research","volume":"523\u2013531","author":"Jaffe","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"key20200714083010_b12-ol-0-0-8803","first-page":"1860","article-title":"Report of the committee on hodgkin's disease staging classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res."},{"key":"key20200714083010_b13-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","author":"International Non-Hodgkin's Lymphoma Prognostic Factors Project","year":"1993","journal-title":"N Engl J Med"},{"key":"key20200714083010_b14-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"key20200714083010_b15-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"916","DOI":"10.6004\/jnccn.2014.0125","article-title":"Non-Hodgkin's lymphomas, version 2.2014","volume":"12","author":"Zelenetz","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"key":"key20200714083010_b16-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"key20200714083010_b17-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the eastern cooperative oncology group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"key20200714083010_b18-ol-0-0-8803","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"The non-hodgkin's lymphoma classification project","volume":"89","author":"A clinical evaluation of the international lymphoma study group classification of non-hodgkin's lymphoma","year":"1997","journal-title":"Blood"},{"key":"key20200714083010_b19-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","article-title":"New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. Non-hodgkin's lymphoma classification project","volume":"16","author":"Armitage","year":"1998","journal-title":"J Clin Oncol"},{"key":"key20200714083010_b20-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s12029-013-9519-1","article-title":"A retrospective analysis of clinicopathological characteristics, treatment, and outcome of 27 patients of primary intestinal lymphomas","volume":"44","author":"Khosla","year":"2013","journal-title":"J Gastrointest Cancer"},{"key":"key20200714083010_b21-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s12032-010-9783-x","article-title":"Clinical prognostic analysis of 116 patients with primary intestinal non-hodgkin lymphoma","volume":"29","author":"Gou","year":"2012","journal-title":"Med Oncol"},{"key":"key20200714083010_b22-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1186\/1471-2407-11-321","article-title":"Multicenter retrospective analysis of 581 patients with primary intestinal non-hodgkin lymphoma from the Consortium for Improving Survival of Lymphoma (CISL)","volume":"11","author":"Kim","year":"2011","journal-title":"BMC Cancer"},{"key":"key20200714083010_b23-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1182\/blood-2010-06-288480","article-title":"Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: Surgical resection followed by chemotherapy versus chemotherapy alone","volume":"117","author":"Kim","year":"2011","journal-title":"Blood"},{"key":"key20200714083010_b24-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1080\/10428190600687653","article-title":"Primary lymphomas of the cervix and uterus: The University of Pennsylvania's experience and a review of the literature","volume":"47","author":"Frey","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"key20200714083010_b25-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1056\/NEJM199807023390104","article-title":"Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma","volume":"339","author":"Miller","year":"1998","journal-title":"N Engl J Med"},{"key":"key20200714083010_b26-ol-0-0-8803","first-page":"1471","article-title":"Pathologic character and diagnosis of female primary genital system diffuse large B cell lymphoma","volume":"21","author":"Cheng","year":"2017","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"key20200714083010_b27-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1093\/annonc\/mdt192","article-title":"Primary diffuse large B-cell lymphoma of the breast: Looking at pathogenesis, clinical issues and therapeutic options","volume":"24","author":"Aviv","year":"2013","journal-title":"Ann Oncol"},{"key":"key20200714083010_b28-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1097\/01.sla.0000254418.90192.59","article-title":"Primary breast lymphoma: The role of mastectomy and the importance of lymph node status","volume":"245","author":"Jennings","year":"2007","journal-title":"Ann Surg"},{"key":"key20200714083010_b29-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/annonc\/mdm471","article-title":"Primary diffuse large b-cell lymphoma of the breast: Prognostic factors and outcomes of a study by the international extranodal lymphoma study group","volume":"19","author":"Ryan","year":"2008","journal-title":"Ann Oncol"},{"key":"key20200714083010_b30-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/1097-0142(20010215)91:4<629::AID-CNCR1045>3.0.CO;2-Q","article-title":"Localized non-Hodgkin lymphoma involving the thyroid gland","volume":"91","author":"Ha","year":"2001","journal-title":"Cancer"},{"key":"key20200714083010_b31-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1007\/BF02067333","article-title":"Non-Hodgkin's lymphoma of the thyroid: Is more than biopsy necessary?","volume":"16","author":"Pyke","year":"1992","journal-title":"World J Surg"},{"key":"key20200714083010_b32-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ejso.2007.04.016","article-title":"Surgical trends in the management of thyroid lymphoma","volume":"34","author":"Meyer-Rochow","year":"2008","journal-title":"Eur J Surg Oncol"},{"key":"key20200714083010_b33-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"5711","DOI":"10.1200\/JCO.2006.08.2941","article-title":"Primary central nervous system lymphoma: The memorial sloan-kettering cancer center prognostic model","volume":"24","author":"Abrey","year":"2006","journal-title":"J Clin Oncol"},{"key":"key20200714083010_b34-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/S0140-6736(09)61416-1","article-title":"High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: A randomised phase 2 trial","volume":"374","author":"Ferreri","year":"2009","journal-title":"Lancet"},{"key":"key20200714083010_b35-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","article-title":"Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (matrix regimen) in patients with primary cns lymphoma: Results of the first randomisation of the international extranodal lymphoma study group-32 (ielsg32) phase 2 trial","volume":"3","author":"Ferreri","year":"2016","journal-title":"Lancet Haematol"},{"key":"key20200714083010_b36-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1016\/S1470-2045(15)00076-5","article-title":"Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: Guidelines from the european association for neuro-oncology","volume":"16","author":"Hoang-Xuan","year":"2015","journal-title":"Lancet Oncol"},{"key":"key20200714083010_b37-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1200\/JCO.2013.50.4910","article-title":"Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: Final results and long-term outcome","volume":"31","author":"Morris","year":"2013","journal-title":"J Clin Oncol"},{"key":"key20200714083010_b38-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/s11940-006-0024-8","article-title":"Primary central nervous system lymphoma","volume":"8","author":"Pels","year":"2006","journal-title":"Curr Treat Options Neurol"},{"key":"key20200714083010_b39-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"4730","DOI":"10.1200\/JCO.2007.12.5062","article-title":"Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma","volume":"25","author":"Shah","year":"2007","journal-title":"J Clin Oncol"},{"key":"key20200714083010_b40-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/S1470-2045(10)70229-1","article-title":"High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): A phase 3, randomised, non-inferiority trial","volume":"11","author":"Thiel","year":"2010","journal-title":"Lancet Oncol"},{"key":"key20200714083010_b41-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1007\/s00432-017-2423-5","article-title":"Early whole brain radiotherapy in primary CNS lymphoma: Negative impact on quality of life in the randomized G-PCNSL-SG1 trial","volume":"143","author":"Herrlinger","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"key":"key20200714083010_b42-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"4643","DOI":"10.1200\/JCO.2002.11.013","article-title":"Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation therapy oncology group study 93-10","volume":"20","author":"DeAngelis","year":"2002","journal-title":"J Clin Oncol"},{"key":"key20200714083010_b43-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","article-title":"Ibrutinib unmasks critical role of bruton tyrosine kinase in primary cns lymphoma","volume":"7","author":"Grommes","year":"2017","journal-title":"Cancer Discov"},{"key":"key20200714083010_b44-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1182\/blood-2017-01-764209","article-title":"PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma","volume":"129","author":"Nayak","year":"2017","journal-title":"Blood"},{"key":"key20200714083010_b45-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s00401-011-0891-2","article-title":"Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma","volume":"122","author":"Montesinos-Rongen","year":"2011","journal-title":"Acta Neuropathol"},{"key":"key20200714083010_b46-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.humpath.2013.10.023","article-title":"CD79B and MYD88 mutations in diffuse large B-cell lymphoma","volume":"45","author":"Kim","year":"2014","journal-title":"Hum Pathol"},{"key":"key20200714083010_b47-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/neup.12405","article-title":"Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma","volume":"37","author":"Zheng","year":"2017","journal-title":"Neuropathology"},{"key":"key20200714083010_b48-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"42","DOI":"10.5414\/NP300698","article-title":"PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL)","volume":"33","author":"Berghoff","year":"2014","journal-title":"Clin Neuropathol"},{"key":"key20200714083010_b49-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","article-title":"Targetable genetic features of primary testicular and primary central nervous system lymphomas","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood"},{"key":"key20200714083010_b50-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","article-title":"CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the mabthera international trial (MInT) group","volume":"12","author":"Pfreundschuh","year":"2011","journal-title":"Lancet Oncol"},{"key":"key20200714083010_b51-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1007\/s00277-012-1507-1","article-title":"Treatment of gastrointestinal diffuse large B cell lymphoma in China: A 10-year retrospective study of 114 cases","volume":"91","author":"Li","year":"2012","journal-title":"Ann Hematol"},{"key":"key20200714083010_b52-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1756-8722-5-49","article-title":"Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the consortium for improving survival of lymphoma (CISL)","volume":"5","author":"Kim","year":"2012","journal-title":"J Hematol Oncol"},{"key":"key20200714083010_b53-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/COC.0b013e318209aa12","article-title":"The role of genotype in 104 cases of diffuse large B-cell lymphoma primary of breast","volume":"35","author":"Aviles","year":"2012","journal-title":"Am J Clin Oncol"},{"key":"key20200714083010_b54-ol-0-0-8803","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1182\/blood.V128.22.4228.4228","article-title":"Primary breast diffuse large B cell lymphoma in the rituximab era: Outcomes of a multicenter retrospective study by the lymphoma and leukemia committee of chinese geriatric oncology society(LLC-CGOS)","volume":"128","author":"Hu","year":"2016","journal-title":"Blood"},{"key":"key20200714083010_b55-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.2147\/OTT.S98566","article-title":"Diffuse large B-cell lymphoma of the breast: Prognostic factors and treatment outcomes","volume":"9","author":"Sun","year":"2016","journal-title":"Onco Ther"},{"key":"key20200714083010_b56-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"4930","DOI":"10.1182\/blood-2006-09-047068","article-title":"Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy","volume":"109","author":"Nyman","year":"2007","journal-title":"Blood"},{"key":"key20200714083010_b57-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-09-0113","article-title":"A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy","volume":"15","author":"Choi","year":"2009","journal-title":"Clin Cancer Res"},{"key":"key20200714083010_b58-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.2169\/internalmedicine.49.3941","article-title":"Primary bilateral adrenal diffuse large B-cell lymphoma demonstrating adrenal failure","volume":"49","author":"Horiguchi","year":"2010","journal-title":"Intern Med"},{"key":"key20200714083010_b59-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/bjh.12753","article-title":"A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era","volume":"165","author":"Hosein","year":"2014","journal-title":"Br J Haematol"},{"key":"key20200714083010_b60-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1097\/PAS.0000000000000592","article-title":"Frequent MYD88 L265P and CD79B mutations in primary breast diffuse large B-cell lymphoma","volume":"40","author":"Taniguchi","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"key20200714083010_b61-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1007\/s00277-017-3094-7","article-title":"Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of MYD88 and CD79B mutations","volume":"96","author":"Cao","year":"2017","journal-title":"Ann Hematol"},{"key":"key20200714083010_b62-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1158\/1078-0432.CCR-05-1699","article-title":"Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin","volume":"12","author":"Lin","year":"2006","journal-title":"Clin Cancer Res"},{"key":"key20200714083010_b63-ol-0-0-8803","first-page":"1063","article-title":"BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma","volume":"9","author":"Braaten","year":"2003","journal-title":"Clin Cancer Res"},{"key":"key20200714083010_b64-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s00401-016-1536-2","article-title":"Genomic characterization of primary central nervous system lymphoma","volume":"131","author":"Fukumura","year":"2016","journal-title":"Acta Neuropathol"},{"key":"key20200714083010_b65-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/00000478-200005000-00001","article-title":"Malignant lymphoma of the thyroid gland: A clinicopathologic study of 108 cases","volume":"24","author":"Derringer","year":"2000","journal-title":"Am J Surg Pathol"},{"key":"key20200714083010_b66-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s12185-009-0289-2","article-title":"Diffuse large B-cell lymphoma with central nervous system relapse: Prognosis and risk factors according to retrospective analysis from a single-center experience","volume":"89","author":"Shimazu","year":"2009","journal-title":"Int J Hematol"},{"key":"key20200714083010_b67-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3109\/10428199909145746","article-title":"Primary bilateral adrenal lymphoma associated with idiopathic thrombocytopenic purpura","volume":"35","author":"Yamamoto","year":"1999","journal-title":"Leuk Lymphoma"},{"key":"key20200714083010_b68-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1200\/JCO.1995.13.10.2530","article-title":"Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy","volume":"13","author":"Sonneveld","year":"1995","journal-title":"J Clin Oncol"},{"key":"key20200714083010_b69-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1200\/JCO.1997.15.8.2945","article-title":"Elderly patients with aggressive non-Hodgkin's lymphoma: Disease presentation, response to treatment, and survival-a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years","volume":"15","author":"Bastion","year":"1997","journal-title":"J Clin Oncol"},{"key":"key20200714083010_b70-ol-0-0-8803","first-page":"229","article-title":"Early relapse in the central nervous system-after achieving complete response in primary vaginal lymphoma","volume":"53","author":"Hayase","year":"2012","journal-title":"Rinsho Ketsueki"},{"key":"key20200714083010_b71-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ygyno.2004.12.035","article-title":"Primary ovarian large B-cell lymphoma in patient with juvenile rheumatoid arthritis treated with low dose Methotrexate","volume":"97","author":"Yildirim","year":"2005","journal-title":"Gynecol Oncol"},{"key":"key20200714083010_b72-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1525-1438.2006.00747.x","article-title":"Non-Hodgkin's lymphoma mimicking gynecological malignancies of the vagina and cervix: A report of four cases","volume":"17","author":"Cohn","year":"2007","journal-title":"Int J Gynecol Cancer"},{"key":"key20200714083010_b73-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1093\/annonc\/mdf175","article-title":"Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: A risk model","volume":"13","author":"Hollender","year":"2002","journal-title":"Ann Oncol"},{"key":"key20200714083010_b74-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1111\/bjh.14325","article-title":"Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement","volume":"175","author":"El-Galaly","year":"2016","journal-title":"Br J Haematol"},{"key":"key20200714083010_b75-ol-0-0-8803","first-page":"405","article-title":"A case report and review of the literature","volume":"30","author":"Primary adrenal lymphoma with secondary central nervous system involvement","year":"2013","journal-title":"Turk J Haematol"},{"key":"key20200714083010_b76-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1038\/bcj.2013.28","article-title":"High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites","volume":"3","author":"Kraan","year":"2013","journal-title":"Blood Cancer J"},{"key":"key20200714083010_b77-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.1158\/1078-0432.CCR-12-0845","article-title":"Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas","volume":"18","author":"Gonzalez-Aguilar","year":"2012","journal-title":"Clin Cancer Res"},{"key":"key20200714083010_b78-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/pin.12439","article-title":"Clinicopathological features of 49 primary gastrointestinal diffuse large B-cell lymphoma cases; comparison with location, cell-of-origin, and frequency of MYD88 L265P","volume":"66","author":"Nagakita","year":"2016","journal-title":"Pathol Int"},{"key":"key20200714083010_b79-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1080\/1042819021000006475","article-title":"Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma","volume":"43","author":"Chua","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"key20200714083010_b80-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/bjc.2014.405","article-title":"A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma","volume":"111","author":"Cheah","year":"2014","journal-title":"Br J Cancer"},{"key":"key20200714083010_b81-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3109\/08880019009034320","article-title":"Cerebrospinal fluid and plasma methotrexate levels following high-dose regimen given as a 3-hour intravenous infusion in children with nonHodgkin's lymphoma","volume":"7","author":"Vassal","year":"1990","journal-title":"Pediatr Hemat Oncol"},{"key":"key20200714083010_b82-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1093\/annonc\/mdl434","article-title":"The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma","volume":"18","author":"Arkenau","year":"2007","journal-title":"Ann Oncol"},{"key":"key20200714083010_b83-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1182\/blood-2008-10-182253","article-title":"CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: An analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)","volume":"113","author":"Boehme","year":"2009","journal-title":"Blood"},{"key":"key20200714083010_b84-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s40880-016-0150-y","article-title":"New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: A retrospective study","volume":"35","author":"Cai","year":"2016","journal-title":"Chin J Cancer"},{"key":"key20200714083010_b85-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/2162-3619-2-19","article-title":"Clinicopathological analysis of primary adrenal diffuse large B-cell lymphoma: Effectiveness of rituximab-containing chemotherapy including central nervous system prophylaxis","volume":"2","author":"Ichikawa","year":"2013","journal-title":"Exp Hematol Oncol"},{"key":"key20200714083010_b86-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/bjh.14392","article-title":"Diffuse large B-cell lymphoma with testicular involvement: Outcome and risk of CNS relapse in the rituximab era","volume":"176","author":"Kridel","year":"2017","journal-title":"Br J Haematol"},{"key":"key20200714083010_b87-ol-0-0-8803","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/annonc\/mdh013","article-title":"Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: Influence of rituximab","volume":"15","author":"Feugier","year":"2004","journal-title":"Ann Oncol"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T08:54:22Z","timestamp":1594716862000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2018.8803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,24]]},"references-count":87,"URL":"https:\/\/doi.org\/10.3892\/ol.2018.8803","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,24]]}}}